• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

L74V 增加了含有非核苷类逆转录酶耐药突变 L100I+K103N 和 K101E+G190S 的 HIV-1 病毒粒子中的逆转录酶含量,从而导致适应性增加。

L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.

机构信息

Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.

出版信息

J Gen Virol. 2013 Jul;94(Pt 7):1597-1607. doi: 10.1099/vir.0.050914-0. Epub 2013 Mar 27.

DOI:10.1099/vir.0.050914-0
PMID:23535575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3709637/
Abstract

The fitness of non-nucleoside reverse transcriptase inhibitor (NNRTI) drug-resistant reverse transcriptase (RT) mutants of HIV-1 correlates with the amount of RT in the virions and the RNase H activity of the RT. We wanted to understand the mechanism by which secondary NNRTI-resistance mutations, L100I and K101E, and the nucleoside resistance mutation, L74V, alter the fitness of K103N and G190S viruses. We measured the amount of RT in virions and the polymerization and RNase H activities of mutant RTs compared to wild-type, K103N and G190S. We found that L100I, K101E and L74V did not change the polymerization or RNase H activities of K103N or G190S RTs. However, L100I and K101E reduced the amount of RT in the virions and subsequent addition of L74V restored RT levels back to those of G190S or K103N alone. We conclude that fitness changes caused by L100I, K101E and L74V derive from their effects on RT content.

摘要

HIV-1 非核苷类逆转录酶抑制剂(NNRTI)耐药逆转录酶(RT)突变体的适应性与病毒粒子中的 RT 含量和 RT 的 RNase H 活性相关。我们希望了解次要 NNRTI 耐药突变 L100I 和 K101E 以及核苷耐药突变 L74V 如何改变 K103N 和 G190S 病毒的适应性。我们测量了病毒粒子中 RT 的含量以及与野生型、K103N 和 G190S 相比突变 RT 的聚合和 RNase H 活性。我们发现 L100I、K101E 和 L74V 并未改变 K103N 或 G190S RT 的聚合或 RNase H 活性。然而,L100I 和 K101E 降低了病毒粒子中的 RT 含量,随后添加 L74V 将 RT 水平恢复到仅 G190S 或 K103N 的水平。我们得出结论,L100I、K101E 和 L74V 引起的适应性变化源于它们对 RT 含量的影响。

相似文献

1
L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.L74V 增加了含有非核苷类逆转录酶耐药突变 L100I+K103N 和 K101E+G190S 的 HIV-1 病毒粒子中的逆转录酶含量,从而导致适应性增加。
J Gen Virol. 2013 Jul;94(Pt 7):1597-1607. doi: 10.1099/vir.0.050914-0. Epub 2013 Mar 27.
2
Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.具有非核苷类逆转录酶抑制剂耐药突变的 HIV-1 在细胞培养中的适应性降低与病毒粒子中逆转录酶含量和 RNase H 活性的相对水平相关。
J Virol. 2010 Sep;84(18):9377-89. doi: 10.1128/JVI.00618-10. Epub 2010 Jun 30.
3
Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.逆转录酶骨架可改变非核苷逆转录酶突变体 K101E+G190S 的聚合和 RNase 活性。
J Gen Virol. 2013 Oct;94(Pt 10):2297-2308. doi: 10.1099/vir.0.054999-0. Epub 2013 Jun 26.
4
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.HIV-1依非韦伦耐药突变体的相对复制适应性:与临床治疗期间的频率相关性以及核苷类耐药突变L74V对K103N + L100I降低的适应性进行补偿的证据
Virology. 2006 Sep 15;353(1):184-92. doi: 10.1016/j.virol.2006.05.021. Epub 2006 Jun 21.
5
The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.对非核苷类逆转录酶抑制剂产生耐药性的HIV-1逆转录酶突变体G190S和G190A,其核糖核酸酶H活性降低,且从tRNA(Lys,3)起始的DNA合成减少,这与复制效率降低相关。
Virology. 2006 May 10;348(2):462-74. doi: 10.1016/j.virol.2006.01.014. Epub 2006 Feb 28.
6
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.非核苷类逆转录酶抑制剂依非韦伦可刺激携带某些非核苷耐药突变的人类免疫缺陷病毒 1 型的复制。
Virology. 2010 Jul 5;402(2):228-37. doi: 10.1016/j.virol.2010.03.018. Epub 2010 Apr 18.
7
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
8
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.非核苷类逆转录酶抑制剂耐药的 HIV 在感染早期受到依非韦伦的刺激。
J Virol. 2011 Oct;85(20):10861-73. doi: 10.1128/JVI.05116-11. Epub 2011 Aug 10.
9
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.P236L地拉韦定耐药的1型人类免疫缺陷病毒突变体复制存在缺陷,并且在RNA 5'端和DNA 3'端导向的核糖核酸酶H活性方面均表现出改变。
J Virol. 1999 Jul;73(7):5803-13. doi: 10.1128/JVI.73.7.5803-5813.1999.
10
Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.1型人类免疫缺陷病毒逆转录酶抑制剂耐药性突变相互作用对表型易感性的影响
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300. doi: 10.1089/aid.2007.0244.

引用本文的文献

1
A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.对猿猴/人类免疫缺陷病毒(SHIV)进化的时空评估揭示了宿主内一个高度动态的过程。
PLoS Pathog. 2017 May 25;13(5):e1006358. doi: 10.1371/journal.ppat.1006358. eCollection 2017 May.
2
Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain.引物ID为下一代测序平台提供信息,并揭示HIV-1逆转录酶编码域中预先存在的耐药性突变。
AIDS Res Hum Retroviruses. 2015 Jun;31(6):658-68. doi: 10.1089/AID.2014.0031. Epub 2015 Apr 2.

本文引用的文献

1
Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.具有非核苷类逆转录酶抑制剂耐药突变的 HIV-1 在细胞培养中的适应性降低与病毒粒子中逆转录酶含量和 RNase H 活性的相对水平相关。
J Virol. 2010 Sep;84(18):9377-89. doi: 10.1128/JVI.00618-10. Epub 2010 Jun 30.
2
HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.来自阿根廷的垂直感染患者的1型艾滋病毒基因型耐药谱揭示了K103N+L100I和L74V突变之间的关联。
Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571.
3
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.非核苷类逆转录酶抑制剂依非韦伦可刺激携带某些非核苷耐药突变的人类免疫缺陷病毒 1 型的复制。
Virology. 2010 Jul 5;402(2):228-37. doi: 10.1016/j.virol.2010.03.018. Epub 2010 Apr 18.
4
Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.含65R、74V、184V和65R + 74V突变的HIV-1逆转录酶体外持续合成能力的比较分析。
Antiviral Res. 2009 Sep;83(3):317-23. doi: 10.1016/j.antiviral.2009.06.002. Epub 2009 Jun 23.
5
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.商业数据库中K65R、L74V及其他HIV-1逆转录酶耐药性突变的流行情况、基因型关联及表型特征
Antivir Ther. 2008;13(2):189-97.
6
Rationale and uses of a public HIV drug-resistance database.一个公共艾滋病毒耐药性数据库的基本原理及用途。
J Infect Dis. 2006 Sep 15;194 Suppl 1(Suppl 1):S51-8. doi: 10.1086/505356.
7
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.HIV-1依非韦伦耐药突变体的相对复制适应性:与临床治疗期间的频率相关性以及核苷类耐药突变L74V对K103N + L100I降低的适应性进行补偿的证据
Virology. 2006 Sep 15;353(1):184-92. doi: 10.1016/j.virol.2006.05.021. Epub 2006 Jun 21.
8
HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.对非核苷类逆转录酶抑制剂耐药的HIV-1逆转录酶突变体不会对DNA合成产生不利影响:预稳态和稳态动力学研究。
J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):405-11. doi: 10.1097/01.qai.0000222288.90201.33.
9
The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.对非核苷类逆转录酶抑制剂产生耐药性的HIV-1逆转录酶突变体G190S和G190A,其核糖核酸酶H活性降低,且从tRNA(Lys,3)起始的DNA合成减少,这与复制效率降低相关。
Virology. 2006 May 10;348(2):462-74. doi: 10.1016/j.virol.2006.01.014. Epub 2006 Feb 28.
10
A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.病毒复制能力的丧失与携带K65R和L74V双脱氧核苷抗性替代的人类免疫缺陷病毒逆转录酶改变的DNA聚合动力学相关。
J Biol Chem. 2004 Jun 11;279(24):25489-96. doi: 10.1074/jbc.M313534200. Epub 2004 Mar 23.